Clinical safety of tocilizumab in rheumatoid arthritis

Bibliography

• Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009;5:531-41
   PubMed Web of Science ®Google Scholar
• Moots RJ, Ostor AJK, Isaacs JD. Will treatment of rheumatoid arthritis with an IL-6R inhibitor help facilitate the ‘age of remission’? Expert Opin Investig Drugs 2009;18:1687-99
   PubMed Web of Science ®Google Scholar
• Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008;2:75-82
   PubMedGoogle Scholar
• Oldfield V, Dhillon S, Plosker GL. Tocilizumab. A review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609-32
   PubMed Web of Science ®Google Scholar
• Jones J, Sebba A, Gu J, Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab monotherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222-32
   PubMed Web of Science ®Google Scholar
• An MM, Zou Z, Shen H, The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol 2010;66:49-59
   PubMed Web of Science ®Google Scholar
• Bergman GJD, Hochberg MC, Boers M, Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum 2010;39:425-41
   PubMed Web of Science ®Google Scholar
• Van Vollenhoven RF, Scali JJ, Curtis JR, Safety of tocilizumab in patients with rheumatoid arthritis: analysis of median of 3.1 years of treatment in long-term extension studies. European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology [poster SAT0172]; 16 – 19 June in Rome, Italy; 2010
   Google Scholar
• European Medicines Agency. RoActemra (tocilizumab). Summary of Product Characteristics. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product _Information/human/000955/WC500054890.pdf [Accessed 25 Augest 2010]
   Google Scholar
• Tamaki K, Kogata Y, Sugiyama D, Diagnostic accuracy of serum procalcitonin concentrations for detecting systemic bacterial infection in patients with systemic autoimmune diseases. J Rheumatol 2008;35:114-19
   PubMed Web of Science ®Google Scholar
• Furst DE, Keystone EC, Fleischmann R, Updated consensus statement on biologic agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010;69(Suppl I):i2-29
   PubMedGoogle Scholar
• Van Vollenhoven RF, Keystone EC, Furie R, Gastrointestinal safety in patients with rheumatoid arthritis treated with tocilizumab: data from Roche clinical trials [abstract 1613]. Arthritis Rheum 2009;60(Suppl):S602
   Google Scholar
• Hong DS, Angelo LS, Kurzrock R. Interleukin-6 and its receptor in cancer. Implications for translational therapeutics. Cancer 2007;110:1911-28
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Nishimoto N, Inoue E, Incidence of malignancies in Japanese rheumatoid arthritis patients treated with tocilizumab in comparison to those in an observational cohort of Japanese patients and a Japanese population database [abstract OP0228]. Ann Rheum Dis 2007;66(Suppl 2):122-3
   Google Scholar
• Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and impact of treatment. Semin Arthritis Rheum 2009;38:372-81
   PubMed Web of Science ®Google Scholar
• Nakamura I, Omata Y, Naito M, Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol 2009;36:459-60
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Kawakami A, Sakamoto N, A fatal case of acute exacerbation of interstitial lung disease in a patient with rheumatoid arthritis during treatment with tocilizumab. Rheumatol Int 2010. [Epub ahead of print]
   Google Scholar
• Nakamura M, Tokura Y. Tocilizumab-induced erythroderma. Eur J Dermatol 2009;19:273-4
   PubMed Web of Science ®Google Scholar
• Yoshiki R, Nakamura M, Tokura Y. Drug eruption induced by IL-6 receptor inhibitor tocilizumab. J Eur Acad Dermatol Venereol 2010;24:495-6
   PubMed Web of Science ®Google Scholar
• Sugiura F, Kojima T, Oguchi T, A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. Mod Rheumatol 2009;19:199-203
   PubMed Web of Science ®Google Scholar
• Kobayashi K, Okamoto Y, Inoue H, Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis. Intern Med 2009;48:1307-9
   PubMed Web of Science ®Google Scholar
• Clark DWJ, Coulter DM, Besag FMC. Randomized controlled trials and assessment of drug safety. Drug Saf 2008;31:1057-61
   PubMed Web of Science ®Google Scholar
• Taylor WJ, Weatherall M. What are open-label extension studies for? J Rheumatol 2006;33:642-3
   PubMed Web of Science ®Google Scholar
• Vandenbroucke JP, Psaty BM. Benefits and risks of drug treatments. How to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008;300:2417-19
   PubMed Web of Science ®Google Scholar
• Littman BH. Tocilizumab and missed personalized medicine opportunities for patients with rheumatoid arthritis? Arthritis Rheum 2009;60:1565-6
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987-97
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Burgos-Vargas R, Ambs P, LITHE: tocilizumab inhibits radiographic progression and improves physical function in rheumatoid arthritis patients at 2 years with increasing clinical efficacy over time [abstract 637]. Arthritis Rheum 2009;60(Suppl):S238-9
   Google Scholar
• Emery P, Keystone E, Tony HP, IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516-23
   PubMed Web of Science ®Google Scholar
• Genovese MC, McKay JD, Nasonov EL, Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs. The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
   PubMed Web of Science ®Google Scholar